Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 14, 2021

SELL
$31.0 - $55.72 $700,941 - $1.26 Million
-22,611 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$37.09 - $48.97 $1.39 Million - $1.83 Million
-37,389 Reduced 62.32%
22,611 $839,000
Q3 2020

Nov 16, 2020

SELL
$40.47 - $45.5 $530,318 - $596,232
-13,104 Reduced 17.93%
60,000 $2.47 Million
Q2 2020

Aug 14, 2020

BUY
$32.57 - $42.83 $106,862 - $140,525
3,281 Added 4.7%
73,104 $2.96 Million
Q1 2020

May 15, 2020

SELL
$23.3 - $45.96 $62,374 - $123,034
-2,677 Reduced 3.69%
69,823 $2.43 Million
Q4 2019

Feb 14, 2020

BUY
$34.58 - $48.06 $2.51 Million - $3.48 Million
72,500 New
72,500 $3.11 Million
Q3 2019

Nov 14, 2019

SELL
$36.98 - $48.45 $240,369 - $314,925
-6,500 Closed
0 $0
Q2 2019

Aug 14, 2019

SELL
$35.13 - $55.53 $1 Million - $1.58 Million
-28,500 Reduced 81.43%
6,500 $294,000
Q1 2019

May 15, 2019

BUY
$42.83 - $59.91 $642,450 - $898,650
15,000 Added 75.0%
35,000 $1.9 Million
Q4 2018

Feb 14, 2019

SELL
$37.97 - $60.16 $2.1 Million - $3.33 Million
-55,405 Reduced 73.48%
20,000 $926,000
Q3 2018

Nov 14, 2018

BUY
$56.3 - $67.25 $22,801 - $27,236
405 Added 0.54%
75,405 $4.58 Million
Q2 2018

Aug 14, 2018

SELL
$44.9 - $64.95 $808,200 - $1.17 Million
-18,000 Reduced 19.35%
75,000 $4.7 Million
Q1 2018

May 15, 2018

SELL
$45.35 - $61.65 $90,700 - $123,300
-2,000 Reduced 2.11%
93,000 $4.3 Million
Q4 2017

Feb 14, 2018

SELL
$41.95 - $60.1 $1.05 Million - $1.5 Million
-25,000 Reduced 20.83%
95,000 $4.5 Million
Q3 2017

Nov 14, 2017

BUY
$33.4 - $53.9 $4.01 Million - $6.47 Million
120,000
120,000 $6.46 Million

Others Institutions Holding FGEN

About FIBROGEN INC


  • Ticker FGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,741,200
  • Market Cap $32.8M
  • Description
  • FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...
More about FGEN
Track This Portfolio

Track Weiss Multi Strategy Advisers LLC Portfolio

Follow Weiss Multi Strategy Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Weiss Multi Strategy Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Weiss Multi Strategy Advisers LLC with notifications on news.